Dermata Therapeutics, Inc. (DRMA) stock
DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.62−0.04 (-6.01%)
Close on Nov 13, 2026Market cap $2.50MP/E –Yield –
Earnings
Dermata Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Mar 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$74.00K
EPS, Q3 FY2026
-$0.55
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Dermata Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026after the close | $74.00K | – | -$0.55 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026after the close | – | – | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 13, 2026after the close | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 26, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 14, 2025after the close | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 14, 2025before the open | – | – | -$0.45 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 17, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 14, 2024after the close | – | – | -$2.04 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 15, 2024after the close | – | – | -$0.47 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 21, 2024after the close | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 10, 2023after the close | – | – | -$0.63 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023after the close | – | – | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 21, 2023after the close | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 10, 2022after the close | – | – | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 15, 2022after the close | – | – | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022after the close | – | – | -$0.33 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 28, 2022before the open | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 15, 2021after the close | – | – | -$0.86 | Release |
| Q2 FY2021ended Jun 30, 2021 | Sep 27, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Dermata Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Dermata Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Dermata Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- Results
- Results
- News
- Results
- Results
- Results
- Update
- Update
- Results
- News
- News
- Update
See a number that looks wrong?